Results 51 to 60 of about 3,437 (189)

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies.

PLoS Pathogens, 2019
The clinical application of conventional peptide drugs, such as the HIV-1 fusion inhibitor enfuvirtide, is limited by their short half-life in vivo. To overcome this limitation, we developed a new strategy to extend the in vivo half-life of a short HIV-1
Wenwen Bi, Wei Xu, Liang Cheng, Jing Xue, Qian Wang, Fei Yu, Shuai Xia, Qi Wang, Guangming Li, Chuan Qin, Lu Lu, Lishan Su, Shibo Jiang   +12 more
doaj   +1 more source

Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide

, 2011
The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation.
K Weizsaecker, M Kurowski, C Feiterna-Sperling, B Hoffmeister, D Schürmann   +4 more
core   +1 more source

Five Antiretroviral Drug Class–Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection

Journal of the International Association of Providers of AIDS Care, 2015
Transmitted HIV-1 exhibiting reduced susceptibility to protease and reverse transcriptase inhibitors is well documented but limited for integrase inhibitors and enfuvirtide.
Joseph M. Volpe PhD, Douglas J. Ward MD, Laura Napolitano MD, Pham Phung BS, Jonathan Toma BS, Owen Solberg PhD, Christos J. Petropoulos PhD, Charles M. Walworth MD   +7 more
doaj   +1 more source

Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy

BMC Microbiology, 2003
Background Severe acute respiratory syndrome (SARS) is a febrile respiratory illness. The disease has been etiologically linked to a novel coronavirus that has been named the SARS-associated coronavirus (SARS-CoV), whose genome was recently sequenced ...
Kliger Yossef, Levanon Erez Y
doaj   +1 more source

Subgingival Bacterial Microbiota Profile of People Living With HIV‐1 Under HAART: A Systematic Review

Special Care in Dentistry, Volume 45, Issue 6, November/December 2025.
ABSTRACT Objective This systematic review aimed to assess the available literature on the subgingival bacterial microbiota profiles of PLHIV undergoing HAART. Materials and Methods This research was conducted in accordance with the PRISMA guidelines.
Tatiana Pinheiro de Macedo, Cristiane Gonçalves, Lucio Souza Gonçalves, Priscila Pereira Pavan Vidal, Josué da Costa Lima‐Junior, Mario Vianna Vettore, Rodrigo Carvalho de Souza   +6 more
wiley   +1 more source

Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor

, 2008
We present a model of the pharmacokinetics of enfuvirtide, a potent inhibitor of the fusion of human immunodeficiency virus type 1 (HIV-1) with target cells.
Mohanty, Utkala, Utkala Mohanty, Narendra M. Dixit, Dixit, Narendra M.   +3 more
core   +1 more source

Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. [PDF]

PLoS ONE, 2013
Recently, the covalent binding of a cholesterol moiety to a classical HIV-1 fusion inhibitor peptide, C34, was shown to potentiate its antiviral activity.
Axel Hollmann, Pedro M Matos, Marcelo T Augusto, Miguel A R B Castanho, Nuno C Santos   +4 more
doaj   +1 more source

Fast pH‐Driven Solubilization Method of Realgar (As4S4) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes

Advanced Science, Volume 12, Issue 29, August 7, 2025.
Arsenic trioxide transformed acute promyelocytic leukemia therapy and shows promise against HIV. A new method to solubilize the mineral realgar produces different arsenic species depleting the main arsenic target, nuclear PML protein, and retaining effects on leukemic and HIV reservoir cells, while minimizing off‐target damage.
Bojana Lucic, Douglas Santana Franciscato, Helton Pereira Nogueira, Lara Gallucci, Alceu Totti Silveira Junior, Asmaa Mohamed Ismail, Millie Robinson, Teresa Dallinger, Claudia Gutfleisch, Jochen Kurz, Maytê Toledo, Jessica Dias da Silva Ferraz, Mohammad Tarek, Danilo Dias, Ricardo Sobhie Diaz, Mahmoud ElHefnawi, Mattia Forcato, Hugo P Monteiro, Marina Lusic, Iart Luca Shytaj, Andrea Savarino   +20 more
wiley   +1 more source

Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV‑1

, 2019
Drugs that block HIV-1 entry are relatively limited. Enfuvirtide is a 36-residue synthetic peptide that targets gp41 and blocks viral fusion. However, Enfuvirtide-resistant HIV has been reported, and this peptide drug requires daily injection. Previously,
Rachel L. Tennyson (6445370), Susanne N. Walker, Terumasa Ikeda, Reuben S. Harris (22319), Susanne N. Walker (6445373), Brian R. McNaughton, Terumasa Ikeda (663867), Brian R. McNaughton (1272537), Rachel L. Tennyson, Reuben S. Harris   +9 more
core   +1 more source

Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients

Brazilian Journal of Infectious Diseases, 2015
Antiretroviral therapy has significantly evolved in the last decade, with an increasing number of new drugs and classes. Currently, even heavily experienced patients can be successfully treated with new regimens.
Carlos Brites, Isabella Nóbrega, Eduardo Martins Netto   +2 more
doaj   +1 more source